CEO: Marisol Quintero

Advent Contact: Shahzad Malik; Laura A. Lane

Bridging the innate to adaptive immune response

Highlight (ex Bioncotech) is a clinical-stage, immune-oncology company focused on developing a cutting-edge RNA-based therapies against validated and novel targets in cancer and immune cells

Highlight Therapeutics appoints Dr. Carlos Paya as Executive Chairman

Bioncotech Announces Oncology Clinical Trial Collaboration with MSD Phase II Trial